Atlas Trials

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

Clinical trial NCT05794906 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05794906
Sponsor
Bayer
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Biochemically Recurrent Prostate Cancer
Start date
2023-04-03
Primary completion
2027-07-30
Enrollment
985

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.